Fewer than 10% of individuals that would benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a long-term condition that can be addressed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major obstacles to broad access to the injections that can help people shift considerable weight, says the organization.
GLP-1 Therapy Supply Crisis
Despite the current most optimistic case, the manufacturing of these medications might only reach around 100 million people – less than 10% of eligible patients, according to the health organization.
The advice calls on governments and firms to expand availability, via approaches like voluntary licensing.
Exclusive production rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Drugs Work
These medications mimick a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so users consume fewer calories.
Patients commonly see weight reduction within a few weeks of beginning the weekly injections.
Research suggests people may regain a significant portion within a year of halting the drug, as their normal hunger come back.
To be carrying excess weight raises your likelihood for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the health agency.